Op/Ed Table

Op Eds / Perspectives

Date	Title	Author
August 3, 2009	Shocked	Kathleen Cochrane, Advocate
March 7, 2008	When Registering Trials is No Help	Merrill Goozner, GoozNews blog
July 8, 2008	Opinion: Is there an important pattern in the seemingly uninterrupted failure of drugs and biologics?	Greg Wasson, Advocate
February 8, 2008	Gains Come with Risks, Sometimes Personal Costs?	Peggy Willocks, Advocate
December 10, 2007	Profit Over Common Sense	Paula Wittekind, Advocate
August 10, 2006	New data has patient advocates still asking: Why did Amgen halt its GDNF trials?	Linda Herman, Advocate
June 5, 2006	Putting a Name To It	Paula Wittekind, Editor, Grassroots Connection
May 24, 2006	GDNF poses troubling questions for doctors and drug maker
May 17,2006	What will FDA approval of Exelon mean for the PD community?	Perry Cohen, Director, Parkinson Pipeline Project
March 20, 2006	PRECEPT Trial Participant and PD Advocate CEP-1347 results disappointing, but clinical trials still best hope for a cure	Jean Burns, Advocate
February 17, 2006	Grassroots responses: The Lancet Neurology: GDNF in treatment of Parkinson's disease	Jean Burns, Advocate
July 12, 2005	Open letter to the trial participants using GDNF	Peggy Willocks, Advocate
July 11, 2005	Patients in UK Parkinson's disease study treated unfairly Amnews.com - The Advocate Messenger, Letter to the Editor	Lonnie Napier, State Representative, Kentucky
July 10, 2005	Amgen's GDNF shows signs of effectiveness LA Times, Business Section, letter to the editor, Regarding "Study adds to dispute over drug by Amgen," July 2, 2005	Kristin Suthers
June 8, 2005	Court ruling denies patients compassionate use of GDNF	Linda Herman, Advocate
May 25, 2005	Cephalon, Inc. Halts Clinical Trial of CEP-1347 for Neuroprotection	Linda Herman, Advocate
May, 2005	GDNF and the Patient Perspective on New Therapy Development	Perry Cohen, Director, Parkinson Pipeline Project